|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WDR72 |
Gene summary for WDR72 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WDR72 | Gene ID | 256764 |
| Gene name | WD repeat domain 72 | |
| Gene Alias | AI2A3 | |
| Cytomap | 15q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0007275 | UniProtAcc | A0A087WTC3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 256764 | WDR72 | C38 | Human | Oral cavity | OSCC | 1.66e-10 | 6.34e-01 | 0.172 |
| 256764 | WDR72 | C46 | Human | Oral cavity | OSCC | 8.41e-44 | 8.02e-01 | 0.1673 |
| 256764 | WDR72 | C57 | Human | Oral cavity | OSCC | 3.15e-17 | 5.58e-01 | 0.1679 |
| 256764 | WDR72 | C07 | Human | Oral cavity | OSCC | 3.19e-08 | 1.31e+00 | 0.2491 |
| 256764 | WDR72 | C08 | Human | Oral cavity | OSCC | 2.10e-93 | 1.43e+00 | 0.1919 |
| 256764 | WDR72 | C09 | Human | Oral cavity | OSCC | 2.79e-23 | 7.32e-01 | 0.1431 |
| 256764 | WDR72 | LN22 | Human | Oral cavity | OSCC | 9.81e-18 | 1.20e+00 | 0.1733 |
| 256764 | WDR72 | LN38 | Human | Oral cavity | OSCC | 2.78e-08 | 7.37e-01 | 0.168 |
| 256764 | WDR72 | LN46 | Human | Oral cavity | OSCC | 7.43e-28 | 6.99e-01 | 0.1666 |
| 256764 | WDR72 | LP15 | Human | Oral cavity | LP | 7.46e-16 | 1.31e+00 | 0.2174 |
| 256764 | WDR72 | SYSMH1 | Human | Oral cavity | OSCC | 3.13e-39 | 6.80e-01 | 0.1127 |
| 256764 | WDR72 | SYSMH6 | Human | Oral cavity | OSCC | 2.01e-07 | 1.83e-01 | 0.1275 |
| 256764 | WDR72 | Adj_PTCwithHT_6 | Human | Thyroid | HT | 2.66e-05 | -3.16e-01 | 0.02 |
| 256764 | WDR72 | PTCwithHT_6 | Human | Thyroid | HT | 2.66e-05 | -3.14e-01 | 0.02 |
| 256764 | WDR72 | PTCwithHT_8 | Human | Thyroid | HT | 2.66e-05 | -3.16e-01 | 0.0351 |
| 256764 | WDR72 | PTCwithoutHT_2 | Human | Thyroid | PTC | 1.86e-02 | -3.02e-01 | 0.0419 |
| 256764 | WDR72 | male-WTA | Human | Thyroid | PTC | 6.40e-13 | -1.60e-01 | 0.1037 |
| 256764 | WDR72 | PTC01 | Human | Thyroid | PTC | 7.92e-06 | -2.71e-01 | 0.1899 |
| 256764 | WDR72 | PTC04 | Human | Thyroid | PTC | 4.29e-03 | -2.87e-01 | 0.1927 |
| 256764 | WDR72 | PTC05 | Human | Thyroid | PTC | 5.43e-04 | -1.35e-01 | 0.2065 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007265910 | Cervix | CC | protein localization to plasma membrane | 73/2311 | 284/18723 | 4.95e-10 | 6.73e-08 | 73 |
| GO:19907788 | Cervix | CC | protein localization to cell periphery | 78/2311 | 333/18723 | 1.22e-08 | 9.73e-07 | 78 |
| GO:002241110 | Cervix | CC | cellular component disassembly | 83/2311 | 443/18723 | 6.04e-05 | 8.68e-04 | 83 |
| GO:0030198 | Cervix | CC | extracellular matrix organization | 52/2311 | 301/18723 | 7.43e-03 | 3.98e-02 | 52 |
| GO:0043062 | Cervix | CC | extracellular structure organization | 52/2311 | 302/18723 | 7.92e-03 | 4.17e-02 | 52 |
| GO:0022617 | Cervix | CC | extracellular matrix disassembly | 15/2311 | 63/18723 | 8.52e-03 | 4.40e-02 | 15 |
| GO:0031214 | Cervix | CC | biomineral tissue development | 32/2311 | 169/18723 | 8.73e-03 | 4.48e-02 | 32 |
| GO:0045229 | Cervix | CC | external encapsulating structure organization | 52/2311 | 304/18723 | 9.00e-03 | 4.57e-02 | 52 |
| GO:0110148 | Cervix | CC | biomineralization | 32/2311 | 171/18723 | 1.04e-02 | 4.97e-02 | 32 |
| GO:002241120 | Esophagus | HGIN | cellular component disassembly | 102/2587 | 443/18723 | 8.31e-08 | 4.33e-06 | 102 |
| GO:007265920 | Esophagus | HGIN | protein localization to plasma membrane | 66/2587 | 284/18723 | 1.11e-05 | 3.18e-04 | 66 |
| GO:199077818 | Esophagus | HGIN | protein localization to cell periphery | 71/2587 | 333/18723 | 1.05e-04 | 2.24e-03 | 71 |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:0072659110 | Esophagus | ESCC | protein localization to plasma membrane | 193/8552 | 284/18723 | 1.95e-14 | 1.03e-12 | 193 |
| GO:199077819 | Esophagus | ESCC | protein localization to cell periphery | 217/8552 | 333/18723 | 4.08e-13 | 1.88e-11 | 217 |
| GO:00301984 | Esophagus | ESCC | extracellular matrix organization | 171/8552 | 301/18723 | 6.08e-05 | 4.67e-04 | 171 |
| GO:00430624 | Esophagus | ESCC | extracellular structure organization | 171/8552 | 302/18723 | 7.73e-05 | 5.76e-04 | 171 |
| GO:00452294 | Esophagus | ESCC | external encapsulating structure organization | 172/8552 | 304/18723 | 7.80e-05 | 5.80e-04 | 172 |
| GO:00226172 | Esophagus | ESCC | extracellular matrix disassembly | 39/8552 | 63/18723 | 6.92e-03 | 2.52e-02 | 39 |
| GO:00726597 | Liver | NAFLD | protein localization to plasma membrane | 51/1882 | 284/18723 | 2.97e-05 | 7.83e-04 | 51 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WDR72 | SNV | Missense_Mutation | c.2561N>A | p.Ile854Lys | p.I854K | Q3MJ13 | protein_coding | tolerated(0.57) | benign(0) | TCGA-A1-A0SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| WDR72 | SNV | Missense_Mutation | c.2459N>G | p.Asn820Ser | p.N820S | Q3MJ13 | protein_coding | tolerated(0.05) | benign(0.005) | TCGA-A8-A083-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| WDR72 | SNV | Missense_Mutation | novel | c.357N>A | p.Phe119Leu | p.F119L | Q3MJ13 | protein_coding | tolerated(0.18) | benign(0.115) | TCGA-AC-A23G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
| WDR72 | SNV | Missense_Mutation | novel | c.2672N>T | p.Asn891Ile | p.N891I | Q3MJ13 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WDR72 | SNV | Missense_Mutation | c.674N>G | p.Glu225Gly | p.E225G | Q3MJ13 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-AR-A1AO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| WDR72 | SNV | Missense_Mutation | c.2318N>C | p.Lys773Thr | p.K773T | Q3MJ13 | protein_coding | deleterious(0.03) | possibly_damaging(0.861) | TCGA-C8-A12X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| WDR72 | SNV | Missense_Mutation | rs200899249 | c.161N>T | p.Ala54Val | p.A54V | Q3MJ13 | protein_coding | deleterious(0.01) | probably_damaging(0.909) | TCGA-C8-A12X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| WDR72 | SNV | Missense_Mutation | rs368755797 | c.1802G>A | p.Arg601Gln | p.R601Q | Q3MJ13 | protein_coding | tolerated(0.21) | benign(0.001) | TCGA-D8-A1XF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
| WDR72 | SNV | Missense_Mutation | c.196N>T | p.Thr66Ser | p.T66S | Q3MJ13 | protein_coding | deleterious(0.02) | possibly_damaging(0.723) | TCGA-E2-A1LA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| WDR72 | SNV | Missense_Mutation | novel | c.1324N>A | p.Leu442Met | p.L442M | Q3MJ13 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |